Clinically amyopathic dermatomyositis (CADM), characterized by anti-melanoma differentiation-associated protein 5 (anti-MDA5) antibodies, represents a distinct subgroup within the spectrum of idiopathic inflammatory myopathies (Hallowell and Danoff, 2023). The gene discussed is IFIH1; the disease is clinically amyopathic dermatomyositis.